FDA approves Spark Therapeutics' gene therapy treatment; pricing questions remain
The Food and Drug Administration has approved Luxturna, a new gene therapy developed by Philadelphia-based Spark Therapeutics to treat children and adult patients with an inherited form of vision loss that may result in blindness.
Luxturna becomes the first directly administered gene therapy approved in the United States that targets a disease caused by mutations in a specific gene.
The big question now becomes what Spark will charge for the gene therapy, administered just once, that analysts…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news
More News: Blindness | Children | Eyes | Food and Drug Administration (FDA) | Gene Therapy | Genetics | Health Management | Opthalmology | Pharmaceuticals | USA Health